World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0014724536
Reproduction Date:

Title: Bicifadine  
Author: World Heritage Encyclopedia
Language: English
Subject: Serotonin–norepinephrine–dopamine reuptake inhibitor, DOV-216,303, D-161, Sercloremine, Monoaminergic
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Legal status
  • US: Unscheduled
Routes oral
Pharmacokinetic data
Half-life 1.6 hours
Excretion renal
CAS number  YesY
ATC code None
ChemSpider  YesY
Chemical data
Formula C12H15N 
Mol. mass 173.25 g/mol

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) developed by DOV Pharmaceutical.[1] It has been developed as an analgesic and is currently under development for the treatment of various pain conditions.[2] Phase III trials were completed in 2006 for treating chronic low back pain, and the drug is currently being tested to assess its efficacy in treating pain associated with osteoarthritis, acute post-surgical pain, neuropathic pain and pain associated with dental surgery.[1] Its usefulness in surgical or dental pain is dubious, however, as most monoamine uptake-inhibiting antidepressants have little if any effect in treating acute pain—they are only effective in cases of chronic neuropathic pain (much like their antidepressant properties, the analgesic properties of monoamine uptake inhibitors are not fully manifested until 1–2 weeks of continuous treatment).

Dov ran into difficulties in 2006 after bicifadine failed in Phase III for chronic lower back pain.[3][4]

Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[5] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[6] While its efficacy at the DAT is lower than its efficacy at either the SERT or the NET, it is still capable of increasing the perisynaptic concentration of all three monoamines. Bicifadine is not the first antidepressant drug used in the treatment of pain, as the older tricyclic antidepressants (e.g. desipramine and amitriptyline) and the newer SNRI drug duloxetine have previously been approved for the treatment of neuropathic pain and disorders such as fibromyalgia. Moreover, some weak or atypical opioid drugs such as tramadol and the newer agent tapentadol also function as noradrenaline reuptake inhibitors, a property that contributes to their overall therapeutic effect.

Preliminary results suggest that bicifadine has an analgesic efficacy slightly stronger than codeine and approximately equivalent to tramadol, although side effects such as nausea and headache were more common with bicifadine than with tramadol.[7]

Chemical synthesis

A synthesis has been published which begins with a benzyl cyanide derivative and a halohydrin. The final step in the synthesis is shown below, where thionyl chloride is used to close the pyrrolidine ring.[1]

DOV scientists and their collaborators have also developed several routes to bicifadine and related compounds.[8]


Related compound, cyproximide, has tranquilizing properties.[9]

See also


  1. ^ a b Xu, F.; Murry, J. A.; Simmons, B.; Corley, E.; Fitch, K.; Karady, S.; Tschaen, D. (2006). "Stereocontrolled Synthesis of Trisubstituted Cyclopropanes:  Expedient, Atom-Economical, Asymmetric Syntheses of (+)-Bicifadine and DOV21947". Organic Letters 8 (17): 3885–3888.  
  2. ^ Krieter, P. A.; Gohdes, M.; Musick, T. J.; Duncanson, F. P.; Bridson, W. E. (2007). "Pharmacokinetics, Disposition, and Metabolism of Bicifadine in Humans". Drug Metabolism and Disposition 36 (2): 252–259.  
  3. ^ BioCentury, July 26, 2010
  4. ^ "Euthymics: Balancing act". BioCentury, The Bernstein Report on Biobusiness. December 5, 2011. p. A13. 
  5. ^ Wang, R. I.; Johnson, R. P.; Lee, J. C.; Waite, E. M. (1982). "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain". Journal of Clinical Pharmacology 22 (4): 160–164.  
  6. ^ Basile, A.; Janowsky, A.; Golembiowska, K.; Kowalska, M.; Tam, E.; Benveniste, M.; Popik, P.; Nikiforuk, A.; Krawczyk, M.; Nowak, G.; Krieter, P. A.; Lippa, A. S.; Skolnick, P.; Koustova, E. (2007). "Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain". The Journal of Pharmacology and Experimental Therapeutics 321 (3): 1208–1225.  
  7. ^ [2]
  8. ^ (2006) WO application 2006096810, Skolnick, P.; Basile, A.; Chen, Z., "METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES" 
  9. ^ E. N. Greenblatt and S. R. Safir, U.S. Patent 3,344,026 (1967); Chem. Abstr., 68: 29443m (1968).
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.